DNA hypermethylation as a chemotherapy target

Area of Science:

• Epigenetics and Cancer Biology
• Molecular Oncology

Background:

• Epigenetics involves reversible gene expression changes without altering DNA sequence.
• Aberrant DNA methylation, particularly hypermethylation, is a hallmark of cancer, leading to tumor suppressor gene silencing.
• The disrupted cancer methylome presents a significant therapeutic target.

Purpose of the Study:

• To review recent advances in cancer epigenetic mechanisms.
• To provide an update on the development of DNA methyltransferase inhibitors (DNMTi).
• To discuss the clinical applications, challenges, and future directions of DNMTi in cancer therapy.

Main Methods:

• Review of current literature on epigenetics in cancer.
• Analysis of small molecule inhibitors targeting DNA methyltransferase (DNMT).
• Examination of preclinical and clinical trial data for DNMT inhibitors.

Main Results:

• DNA hypermethylation silences tumor suppressor genes in cancer.
• DNMT inhibitors reverse DNA hypermethylation, leading to gene reactivation.
• Clinical studies show DNMTi can inhibit cancer cell proliferation, promote apoptosis, and enhance chemotherapy efficacy.

Conclusions:

• DNA methylation is a critical epigenetic mechanism in cancer development.
• DNMT inhibitors represent a promising class of anti-cancer therapeutics.
• Continued research is essential to optimize DNMTi efficacy and minimize toxicity for improved clinical outcomes.